SEOM clinical guideline for the management of malignant melanoma (2017)

All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrocal, A., Arance, A., Castellon, V. E., de la Cruz, L., Espinosa, E., Cao, M. G., Larriba, J. L. G., Márquez-Rodas, I., Soria, A., Algarra, S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Clinical Guides in Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785602/
https://www.ncbi.nlm.nih.gov/pubmed/29116432
http://dx.doi.org/10.1007/s12094-017-1768-1
_version_ 1783295631098380288
author Berrocal, A.
Arance, A.
Castellon, V. E.
de la Cruz, L.
Espinosa, E.
Cao, M. G.
Larriba, J. L. G.
Márquez-Rodas, I.
Soria, A.
Algarra, S. M.
author_facet Berrocal, A.
Arance, A.
Castellon, V. E.
de la Cruz, L.
Espinosa, E.
Cao, M. G.
Larriba, J. L. G.
Márquez-Rodas, I.
Soria, A.
Algarra, S. M.
author_sort Berrocal, A.
collection PubMed
description All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
format Online
Article
Text
id pubmed-5785602
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-57856022018-02-01 SEOM clinical guideline for the management of malignant melanoma (2017) Berrocal, A. Arance, A. Castellon, V. E. de la Cruz, L. Espinosa, E. Cao, M. G. Larriba, J. L. G. Márquez-Rodas, I. Soria, A. Algarra, S. M. Clin Transl Oncol Clinical Guides in Oncology All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams. Springer International Publishing 2017-11-07 2018 /pmc/articles/PMC5785602/ /pubmed/29116432 http://dx.doi.org/10.1007/s12094-017-1768-1 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Guides in Oncology
Berrocal, A.
Arance, A.
Castellon, V. E.
de la Cruz, L.
Espinosa, E.
Cao, M. G.
Larriba, J. L. G.
Márquez-Rodas, I.
Soria, A.
Algarra, S. M.
SEOM clinical guideline for the management of malignant melanoma (2017)
title SEOM clinical guideline for the management of malignant melanoma (2017)
title_full SEOM clinical guideline for the management of malignant melanoma (2017)
title_fullStr SEOM clinical guideline for the management of malignant melanoma (2017)
title_full_unstemmed SEOM clinical guideline for the management of malignant melanoma (2017)
title_short SEOM clinical guideline for the management of malignant melanoma (2017)
title_sort seom clinical guideline for the management of malignant melanoma (2017)
topic Clinical Guides in Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785602/
https://www.ncbi.nlm.nih.gov/pubmed/29116432
http://dx.doi.org/10.1007/s12094-017-1768-1
work_keys_str_mv AT berrocala seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT arancea seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT castellonve seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT delacruzl seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT espinosae seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT caomg seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT larribajlg seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT marquezrodasi seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT soriaa seomclinicalguidelineforthemanagementofmalignantmelanoma2017
AT algarrasm seomclinicalguidelineforthemanagementofmalignantmelanoma2017

Ejemplares similares